Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
http://www.roboticsalley.org/documents/RA_GUIDEBOOK_2015_WEB.pdf
44 pages, of 40 advertisement for Ximedica with Titan Sport in the adv
Ximedica dominates the 2nd this Wednesday and to cover
BUILDING A FOUNDATIONAL DEVELOPMENT STRATEGY FOR A SURGICAL ROBOT
Day 2 | 10:30 AM - 12:00 PM Michael Pereira, EVP, Technology &
Operations, Ximedica
COMPUTERS AND SOFTWARE IN MEDICAL ROBOTICS
- AN IP PERSPECTIVE
Day 2 | 1:15 - 2:45 PM
Stephen Durant, Principal, Patent Attorney, Schwegman, Lundberg, Woessner; John Fischer, Principal, Patent Attorney, Schwegman, Lundberg, Woessner; Josue Villalta, Partner, Patent Attorney, Knobbe Martens Olson & Bear, LLP
They had to wait for some of intuitive key patents to expire before showing their cards
Interesting find - would like boards thoughts
Reiza former director at IntelGenx Technologies Corp
http://www.intelgenx.com/investors/stock-price/default.aspx
Reiza Rayman has been the President of Titan Medical Inc. since May 2006. Dr. Rayman served as an Assistant Professor of Department of Surgery at the University of Western Ontario. From 2000 to 2005, he served as Principal Investigator of Robotic Tele-surgery and Hybrid Cardiac Surgery, and CSTAR. He has been a Director of Titan Medical Inc. since 2008. On September 1999, he performed the world's first robotic beating heart cardiac bypass surgery. Dr. Rayman served as a Director of IntelGenx Technologies Corp., from June 2006 to May 21, 2008. Dr. Rayman received training in both biophysics and medicine. During subsequent medical training, Dr. Rayman became interested in minimally invasive surgical (MIS) techniques and devices, and researched the physiologic effects of MIS on infants during prolonged procedures. Additionally, his interest in the device area led to concepts and experimentation using magnetism for bowel retraction during MIS. He holds a PhD in Telesurgery from the University of Western Ontario. Dr. Rayman holds an MSc in Biophysics from the University of Western Ontario and an MD from the University of Toronto.
http://ubimon.doc.ic.ac.uk/Hamlyn2013/m1663.html
Titan Medical Fact Sheet
September 2010
Interesting read before SPORT
http://allaboutroboticsurgery.com/images/Titan_Medical_Fact_Sheet_.pdf
Cadaver - Full Definition
:a dead body; especially :one intended for dissection
Titan Medical Inc. (“Titan” or the “Company“) (TSX: TMD) (OTCQX: TITXF) today announced that it has completed its first successful cadaver lab studies with the SPORT™ Surgical System. Procedures performed included total abdominal hysterectomy, prostatectomy, and ureteroneocystostomy, addressing three key anatomical areas of focus for SPORT™. The cadaver studies were performed by two experienced robotic surgeons from the Company’s Surgeon Advisory Board.
Outlook from SEDAR
Titan continues to focus its efforts on the development of the SPORTTM Surgical System and is continuing its move towards commercialization. On April 16, 2015, the Company announced that effective March 31, 2015 it had signed an agreement with a worldwide supplier of endomechanical devices for the development and supply of single patient use robotic tools. Under the terms of the agreement, the supplier will create customized single patient use tools for Titan’s SPORTTM Surgical System. On May 5, 2015, the Company announced that it had signed an agreement with the James and Sylvia Earl, Simulation to Advance Innovation and Learning (SAIL) Center at Anne Arundel Medical Center (AAMC) in Annapolis, MD, for the development of a training curriculum and post-training assessment of surgeons and surgical teams who would use the SPORTTM Surgical System.
On a regular basis, Titan undertakes a detailed analysis and reasonableness review of its development milestones and related cost estimates.
Over the course of the next twelve months, Titan’s objectives include significantly advancing the development of its robotic surgical system including completion of prototype units for engineering verification in Q4 of 2015. In addition, Titan will undertake human clinical cases utilizing additional prototype units completed in early 2016. On September 7, 2015, the Company entered into a master services agreement with Chiltern International, Inc. (“Chiltern”), formerly Theorem CR, Inc., which will allow the parties to negotiate the provision of clinical trial research services to be provided by Chiltern to Titan from time to time, without having to re-negotiate the terms and conditions for each such service.
The Company anticipates commencing an audit for obtaining CE Mark approval in Q2 2016. As of July 30, 2015, Titan had entered into an agreement with BSI Group America Inc. (“BSI”), a recognized European Notified Body, for BSI to perform the necessary assessments so as to certify Titan’s quality system for compliance with international and European requirements, as required to obtain CE Mark approval to market medical devices in the European Union.
On July 23, 2015, the Company filed with the securities regulators in Ontario, British Columbia and Alberta, a Preliminary Short Form Base Shelf Prospectus, relating to the offering for sale from time to time, during the 25 month period covered by the prospectus, securities with a total offering price of U.S. $45 million. The securities may be offered separately or together, in amounts, at prices and on terms to be determined based on market conditions at the time of the sale and set forth in an accompanying prospectus supplement. The Company currently intends to use the net proceeds from the sale of the securities for the Company’s research and development of a clinical- grade prototype of its SPORTTM Surgical System, pre-clinical trial and regulatory costs and for working capital and other general corporate purposes.
On August 18, 2015, the Company filed with the securities regulators in Ontario, British Columbia and Alberta, a Final Short Form Base Shelf Prospectus, relating to the offering for sale from time to time, during the 25 month period covered by the prospectus, securities with a total offering price of U.S. $45 million.
On October 30, 2015, Titan announced that it had signed a Letter Agreement with Longtai Medical Inc. (‘Longtai’), a Canadian subsidiary of Ningbo Long Hengtai International Trade Co. Ltd., which is incorporated under the laws of China. Under the terms of the Letter Agreement, Longtai will subscribe for and purchase US$4,000,000 worth of Common Shares of Titan under a private placement, at a subscription price of CDN$1.23 per share. The private placement is expected to close on or about November 15, 2015. Titan has granted to Longtai exclusive rights to negotiate with Titan for an exclusive marketing, sales and distribution agreement (“Distributorship Agreement”) for Titan’s SPORTTM Surgical System in the Asia Pacific region for a period of 183 days commencing at closing. Additionally, Longtai has paid to Titan US$2,000,000 as a deposit toward the Distributorship Agreement, which shall be repaid to Longtai in the event that the
Looks like they are slightly delayed
The Company continues with additional rounds of testing as the development of the surgical system progresses and is working toward the build of prototype units ready for engineering verification and first-in-human trials. The engineering verification units, which will incorporate substantially all of the design and engineering work toward the SPORTTM Surgical System, are required to be completed prior to the build of the five first-in-human units. The Company reasonably expects that it will complete the build of two engineering verification units in the fourth quarter of 2015. The first-in-human units are expected to be completed in the first quarter of 2016. The schedule for completion of the 5 first-in human units has been moved to Q1 2016 from Q4 2015 to more accurately reflect realistic completion and delivery dates in line with commencement of clinical trials. Given the progress we have made in the build of the prototype units, we now have a better understanding of the time requirements involved in the build process.
Optimism is the faith that leads to achievement.... Stay positive CUIN2, question to you... Those must be three d glasses the engineer is wearing in the video, could that eventually be Google Glasses
http://www.healthcare.philips.com/main/about/future-of-healthcare/
And a fine looking Sasquatch at that
https://vimeo.com/136196187
No working website, Google the business and you find articles about lawsuits, just throwing it out there as I believe it's relevant, phone number does bring you to a voice prompt of octagon corporation which is somewhat reassuring
Same office??? As Titan??? Am I the only smelling fishy ??? Or is this Wall Street politics???
Titan Medical Inc. 170 University Ave, Suite 1000. Toronto, Ontario M5H 3B3.
Octagon Capital Corporation - Creating Wealth Through Ideas ...
www.octagoncap.com › contact
Toronto. 170 University Avenue, suite 1000 (10th floor) Toronto, Ontario M5H
3B3 Canada Telephone: 416-368-3322
website doesn't work
Octagon Capital Corporation
www.octagoncap.com
By big guys would we be implying Ethicon/Google?
Titan Medical Inc. Announces Public Financing November 3rd, 2015
TORONTO, ON–(Marketwired – November 03, 2015) –
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (OTCQX: TITXF) has announced that it intends to commence an offering of units (the “Units“), each Unit to consist of one common share and a partial or whole common share purchase warrant of the Company, by way of a prospectus supplement (the “Prospectus Supplement“) to the Company’s base shelf prospectus dated August 18, 2015 (together with the Prospectus Supplement, the “Prospectus“), to be filed with securities regulators in Ontario, British Columbia and Alberta and on a private placement basis in the United States, on a fully marketed “best efforts” basis, with the pricing and terms of the offering to be determined in the context of the market (together, the “Offering“).
The Company has engaged a U.S. placement agent as its sole agent for the Offering in the United States and Octagon Capital Corporation to serve as lead agent and sole book-runner in connection with the Offering in Canada.
The Offering is subject to a number of conditions, including, without limitation, receipt of all regulatory approvals. The Units will be qualified for distribution in Ontario, British Columbia and Alberta pursuant to the Prospectus. The net proceeds of the Offering will be used for ongoing development and commercialization of robotic surgical technologies and general working capital requirements.
The tortoise is starting to poke his head, and it looks like his journey is longer and broader than we initially all thought, this is about to get monstrous real soon.. Long and strong!!!!
Adrock that sounds to a tee like Titan talking not a JNJ spokesperson ... What are you taking from that??
He has been holding for 4 years and was told by Valvo about the stock.
He bought twice only $0.96 & $1.55
He has OR buddy's that hold heavy positions....
He was told to dump the money there and never look at it again until one day it was gone or millions in the bank...
He said davinci reps were hypothesizing in OR recently about take over talk, and possible 2:1 intuitive gives two to every one share of Titan
Makes no sense to me but this is what he told me
The interesting part of what he was telling me is that it's because of the specific ip Titan holds that intuitive wants and can't replicate.
But the ip Titan has is what they bought/learned from Olympus and built on
Talked to an Olympus Rep tonight that has been working with John Valvo for last four years. He was telling me that Valvo is currently driving a 70k Volvo that Titan has paid for him. Also the word on the street in the OR is that Intuitive will be the ones buying Titan, reason being because Titan has the IP in a specific area of surgery that has to do with hand and touch when the doc is doing the procedure. He had no feedback about Google/JNJ and did not think they at all a relevant play at this point is robotics surgery
Dr. Joseph F. Amaral (Dr. Joe) is Vice President of Medical Devices and Diagnostics Emerging Technologies for Johnson and Johnson Corporation. In this role he provides scientific leadership to the MD&D sector of Johnson and Johnson Corporation by identifying sustaining, disruptive and/or white space science and technology opportunities of strategic relevance; provides context, and perspective to MD&D companies on arenas of emerging science and technology; and ensures access to game changing science and technology in areas of strategic relevance to MD&D. In this role, particular areas of focus are regenerative medicine, emerging surgical technologies such as robotics and nanotechnologies, and treatment of disorders with significant unmet needs such as sleep apnea.
Most recently, Dr. Amaral was President and CEO of Rhode Island Hospital (RIH) and its pediatric division Hasbro Children’s Hospital from 2000 to 20007 and also served as its COO for 3 1/2 years. This is the state of Rhode Island’s largest private employer, Brown University’s largest teaching affiliate, and the third largest hospital in New England. During this period, he led a financial turnaround while at the same time investing over $450 million in renovation projects, new technologies and new facilities and tripling externally funded research.
He is internationally recognized as a pioneer in laparoscopic (minimally invasive) surgery. He introduced these approaches to Rhode Island and New England in 1990. He has performed approximately 3,000 laparoscopic procedures and trained hundreds of practicing surgeons in these techniques throughout New England, broadly across the U.S., and around the world. He has operated in 20 countries and on five continents.
Dr. Amaral was instrumental in the success of Ultracision, a startup company, by developing with company CEO Tom Davison, Ph.D., the Harmonic Scalpel, the first and still leading ultrasonically activated cutting and coagulating surgical device. He has served as a consultant, advisory board member and board member to multiple leading healthcare biotech and startup companies.
He is Professor of Surgery at Brown University School of Medicine, member of 25+ professional societies, author of 80+ papers and book chapters and has delivered 250+ national and international presentations. Prior to becoming RIH President and CEO, Dr. Amaral was Chairman of the Department of Surgery at Brown University School of Medicine, Chief of Surgery at Rhode Island Hospital, President of University Surgical Associates and Executive Chief of Surgery at Lifespan Affiliated Hospitals
He graduated summa cum laude in 1977 from Providence College, obtained his MD degree from Brown Medical School in 1981 and completed his surgical residency training at Brown University/Rhode Island Hospital in 1989.
Yes indeed
Any chance Medtronic buys Titan??
TITAN AND XIMEDICA, USA Dennis Fowler, EVP Titan John Hargrove, CEO Titan Paige Hargrove, Director of European Market for Titan Frederic Nahon, European Consultant for Titan Corey Libbey, Director Program Management for Ximedica
He is Bertners Strategic Advisor, and has quite the colorful background
Investor Relations Honors & Awards: Global IR Forum
Global Top IRO
Winner, 2013
Nominee, 2014
Global Top IR Program
2nd Place, 2013
Nominee, 2014
Investor Relations Honors & Awards: IR Magazine
Best Investor Relations Officer -- Large Cap
• Winner: 2011, 2012, 2013, 2014
• Finalist: 2010
Grand Prix -- Best Overall Investor Relations -- Large Cap
• Winner: 2011, 2012, 2013, 2014
• Finalist: 2010
Best IR in Health Care
2011, 2012, 2013, 2014
Best M&A IR
Winner: 2014
Finalist: 2011, 2013
Best Earnings Calls
2011
Best Investment Community Meetings
2012, 2014
Best Financial Reporting
Finalist: 2013, 2014
Best Use of Technology for IR
Finalist: 2013
Best IR Website
Finalist: 2011
Best Sustainability
Finalist: 2013
Investor Relations Honors & Awards: Institutional Investor Magazine All-America Executive Team
Best Overall IR Program Medical Devices, Life Sciences, and Diagnostic Tools
Buy-Side Vote
• 1st Place: 2011
• 2nd Place: 2012, 2013, 2014
Sell-Side Vote
• 1st Place: 2011, 2012, 2013, 2014
Best IR Professional Medical Devices, Life Sciences, and Diagnostic Tools
Buy-Side Vote
• 1st Place: 2011, 2013, 2014
• 2nd Place: 2012
Sell-Side Vote
• 1st Place: 2013, 2014
• 2nd Place: 2011, 2012
Please attach a link to this artice
Robots to the rescue in aged health care - CNN
https://apple.news/AuD2eWHz8R3ilcK9s7PgZ1A
"Other advantages of IREP include its capability to include sensory information such as force feedback and intra-abdominal ultrasound and also its suitability for micro-surgery enabling high level accuracy which is not currently feasible with existing systems."
Hargrove INKED IT
*Hargrove not Fowler 28:46 seconds AGM conference call
http://www.titanmedicalinc.com/investor-relations/sport-clips/
AGM Conference
Fowler talked about strategic partnerships in the industry of robotics and the operating room specifically talking to surgeons.
Fowlers finishing sentence was "more to follow"
Ink it, the Titan team is partnered up.
It's been a long ride here's to loosing it all or winning it big!!! SUCK IT FOR PRESIDENT
Maybe 35% Titan 35% Google 30 % Johnson and Johnson ???
One can dream
Time for a leg up some big buys this morning
No mention of Titan